Relmada Therapeutics, Inc. (RLMD) stock
RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.01−0.60 (-16.62%)
Close on Nov 17, 2026Market cap $321.08MP/E –Yield –
Relmada Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Relmada Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$45.99M. For fiscal 2025 it was -$45.79M. The highest annual figure on record is -$1.58M in fiscal 2012.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$45.79M | – |
| FY2024 | Dec 31, 2024 | -$51.76M | – |
| FY2023 | Dec 31, 2023 | -$51.66M | – |
| FY2022 | Dec 31, 2022 | -$103.80M | – |
| FY2021 | Dec 31, 2021 | -$91.87M | – |
| FY2019 | Jun 30, 2019 | -$10.50M | – |
| FY2018 | Jun 30, 2018 | -$6.00M | – |
| FY2017 | Jun 30, 2017 | -$6.47M | – |
| FY2016 | Jun 30, 2016 | -$13.14M | – |
| FY2013 | Dec 31, 2013 | -$2.24M | – |
| FY2012 | Dec 31, 2012 | -$1.58M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$9.61M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$15.07M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$14.60M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$6.72M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$6.40M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$18.07M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$8.80M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$16.66M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$13.26M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$13.04M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$10.25M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$11.63M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$13.27M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$16.51M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$35.88M | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$19.43M | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$37.66M | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$20.92M | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$17.21M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$16.09M | – |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | -$3.67M | – |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | -$2.01M | – |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | -$3.15M | – |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | -$1.67M | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -$2.27M | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -$1.63M | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -$1.13M | – |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | -$979.05K | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | -$1.02M | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | -$1.86M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | -$1.45M | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | -$2.14M | – |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | -$2.83M | – |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | -$3.63M | – |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | -$3.48M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | -$3.22M | – |
| Q3 FY2013CQ3 2013 | Sep 30, 2013 | -$408.70K | – |
See a number that looks wrong?